Veeva Systems Inc. (VEEV): Analyse de Pestle [Jan-2025 MISE À JOUR]

Dans le paysage rapide de la technologie des soins de santé, Veeva Systems Inc. (VEEV) se tient à l'intersection de l'innovation et des défis réglementaires complexes. Cette analyse complète du pilon dévoile les facteurs externes à multiples facettes qui façonnent la trajectoire stratégique de l'entreprise, des réglementations politiques complexes aux progrès technologiques transformateurs. Alors que les soins de santé deviennent de plus en plus basés sur les données et transformés numériquement, la compréhension des forces environnementales, juridiques et économiques nuancées devient primordiale pour comprendre la croissance et la résilience potentielles de Veeva sur un marché mondial dynamique.

Veeva Systems Inc. (VEEV) - Analyse du pilon: facteurs politiques

Règlement sur la confidentialité des données de santé américaine Impact

Les systèmes Veeva doivent se conformer aux réglementations strictes sur la confidentialité des données sur les soins de santé, notamment:

Règlement	Exigences de conformité	Impact potentiel
Hipaa	Sécurité des informations de santé protégés (PHI)	Norme obligatoire de 99,5% de protection des données
RGPD	Restrictions internationales de transfert de données	20 millions d'euros ou 4% de potentiel de pénalité mondiale de rotation

FDA et cadres de réglementation des soins de santé

Paysage de conformité réglementaire:

• 21 CFR Part 11 Conformité des dossiers électroniques
• Règlement sur la cybersécurité des dispositifs médicaux
• Lignes directrices sur la soumission des preuves réelles (RWE)

Considérations de politique commerciale internationale

Les contraintes d'exportation technologique mondiale affectant potentiellement l'expansion internationale de Veeva:

Pays	Restrictions d'exportation technologique	Impact potentiel de l'entreprise
Chine	Limitations de transfert de technologie	Barrière potentiel de 30% sur le marché
UE	Conformité de la loi sur les services numériques	10 à 50 millions d'euros de pénalités potentielles de non-conformité

Politiques d'investissement technologique du gouvernement

US Federal Healthcare Technology Budget Allocations:

• 2024 Investissement en santé numérique: 4,2 milliards de dollars
• Budget de modernisation informatique des soins de santé: 1,8 milliard de dollars
• Cybersécurité dans l'allocation des soins de santé: 750 millions de dollars

Veeva Systems Inc. (VEEV) - Analyse du pilon: facteurs économiques

La croissance des dépenses de la technologie de santé continue à soutenir le positionnement du marché de Veeva

Global Healthcare Inform Market prévoyait atteindre 390,7 milliards de dollars d'ici 2024, avec un TCAC de 13,2%. Revenus annuels de Veeva Systems en 2023: 2,32 milliards de dollars, ce qui représente une croissance de 16% en glissement annuel. Le segment des logiciels de technologie de la santé devrait passer de 167,9 milliards de dollars en 2022 à 272,4 milliards de dollars d'ici 2027.

Segment de marché	Valeur 2022	2027 Valeur projetée	TCAC
Les soins de santé	285,3 milliards de dollars	390,7 milliards de dollars	13.2%
Logiciel de technologie de santé	167,9 milliards de dollars	272,4 milliards de dollars	10.2%

Fluctuations économiques potentielles affectant les budgets de recherche en sciences pharmaceutiques et de la vie

Dépenses pharmaceutiques en R&D en 2023: 238,4 milliards de dollars. Le ralentissement économique potentiel pourrait avoir un impact sur les budgets de recherche. Les clients d'entreprise de Veeva comprennent 70% des 200 meilleures sociétés pharmaceutiques, offrant une certaine stabilité du marché.

Métrique pharmaceutique de R&D	Valeur 2023
Dépenses totales de R&D	238,4 milliards de dollars
Pourcentage de revenus investis dans la R&D	18.2%

Variations des taux de change a un impact sur les sources de revenus internationales

Les revenus internationaux de Veeva en 2023: 687,6 millions de dollars. Les fluctuations des taux de change qui ont un impact sur 12 à 15% des revenus totaux. Euro et yens japonais les plus importantes expositions en devises étrangères.

Devise	2023 Volatilité du taux de change	Impact sur les revenus internationaux
Euro	±4.7%	203,4 millions de dollars
Yen japonais	±3.9%	98,2 millions de dollars

Capital de capital-risque et tendances d'investissement sur les marchés logiciels de la technologie des soins de santé

Investissements en capital-risque de logiciel de technologie de la santé en 2023: 12,6 milliards de dollars. Capitalisation boursière de Veeva Systems: 33,7 milliards de dollars. Financement du capital-risque démontrant une forte confiance des investisseurs dans le secteur des technologies de la santé.

Métrique d'investissement	Valeur 2023
Investissements totaux de VC	12,6 milliards de dollars
Taille moyenne de l'accord	24,3 millions de dollars
Nombre d'offres	519

Veeva Systems Inc. (VEEV) - Analyse du pilon: facteurs sociaux

Demande croissante de solutions de gestion des soins de santé numériques

La taille du marché mondial de la santé numérique a atteint 211,9 milliards de dollars en 2022, prévoyant une augmentation de 536,12 milliards de dollars d'ici 2030, avec un TCAC de 12,5%. Le marché des solutions de logiciels de santé devrait atteindre 50,7 milliards de dollars d'ici 2025.

Segment de marché	Valeur 2022	2030 valeur projetée	TCAC
Marché de la santé numérique	211,9 milliards de dollars	536,12 milliards de dollars	12.5%
Solutions de logiciels de santé	35,2 milliards de dollars	50,7 milliards de dollars	4.6%

Accent croissant sur la prise de décision des soins de santé basée sur les données

Le marché des mégadonnées de la santé estimée à 41,8 milliards de dollars en 2022, devrait atteindre 84,2 milliards de dollars d'ici 2027, avec 15,3% de TCAC. 93% des organisations de soins de santé rapportent des investissements d'analyse de données améliorant l'efficacité opérationnelle.

Métriques d'analyse des données sur les soins de santé	Valeur 2022	2027 Valeur projetée
Marché des mégadonnées des soins de santé	41,8 milliards de dollars	84,2 milliards de dollars
Organisations investissant dans l'analyse des données	93%	N / A

Tendances de travail à distance accélèrent l'adoption de logiciels basés sur le cloud

Le marché des soins de santé dans le cloud computing prévoyait 89,9 milliards de dollars d'ici 2027, augmentant à 17,8% du TCAC. 67% des organisations de soins de santé ont augmenté les investissements technologiques cloud post-pandemiques.

Marché des soins de santé en cloud computing	Valeur 2022	2027 Valeur projetée	TCAC
Taille du marché	39,4 milliards de dollars	89,9 milliards de dollars	17.8%
Organisations augmentant les investissements cloud	67%	N / A	N / A

Importance croissante de l'intégration et de l'interopérabilité de la technologie des soins de santé

Le marché de l'interopérabilité des soins de santé devrait atteindre 4,2 milliards de dollars d'ici 2026, augmentant à 13,2% du TCAC. 80% des prestataires de soins de santé priorisent l'intégration du système pour améliorer les soins aux patients.

Intégration de la technologie des soins de santé	Valeur 2022	2026 Valeur projetée	TCAC
Marché de l'interopérabilité	2,6 milliards de dollars	4,2 milliards de dollars	13.2%
Les fournisseurs priorisent l'intégration du système	80%	N / A	N / A

Veeva Systems Inc. (VEEV) - Analyse du pilon: facteurs technologiques

Innovation continue dans le cloud computing et les plates-formes logicielles en tant que service

Veeva Systems a investi 537,3 millions de dollars dans la recherche et le développement au cours de l'exercice 2023. Les revenus du cloud computing ont atteint 2,16 milliards de dollars en 2023, ce qui représente une croissance de 16% sur l'autre.

Métriques de plate-forme cloud	2023 données
Revenus d'abonnement total dans le cloud	2,16 milliards de dollars
Investissement en R&D	537,3 millions de dollars
Base de clients de plate-forme cloud	1 025 entreprises de sciences de la vie

Intelligence artificielle et intégration d'apprentissage automatique dans la gestion des données sur les soins de santé

Les investissements en IA de Veeva ont totalisé 126,4 millions de dollars en 2023, se concentrant sur les algorithmes d'optimisation des essais cliniques et de traitement des données.

Métriques technologiques de l'IA	2023 statistiques
Investissement de R&D AI	126,4 millions de dollars
Applications de brevet d'apprentissage automatique	17 brevets spécifiques aux soins de santé
Efficacité des essais cliniques améliorés en AI	Réduction de 23% du temps de traitement des données

Technologies de cybersécurité avancées pour protéger les informations médicales sensibles

Veeva a alloué 94,7 millions de dollars aux infrastructures de cybersécurité en 2023, en maintenant SOC 2 TYPE II et HIPAA.

Métriques de cybersécurité	2023 données
Investissement en cybersécurité	94,7 millions de dollars
Niveau de chiffrement des données	Cryptage AES 256 bits
Audits de sécurité annuels	4 Évaluations complètes

Technologies émergentes dans l'analyse des données et les plateformes de recherche clinique

La plate-forme de technologie de recherche clinique de Veeva a traité 4,2 millions de dossiers d'essais cliniques en 2023, avec des capacités d'analyse avancées.

Métriques d'analyse des données	2023 statistiques
Records d'essai cliniques traités	4,2 millions
Vitesse de traitement des données en temps réel	0,03 secondes par dossier
Utilisateurs de la plate-forme de recherche clinique	875 sociétés pharmaceutiques

Veeva Systems Inc. (VEEV) - Analyse du pilon: facteurs juridiques

Exigences de conformité strictes avec HIPAA et réglementation mondiale de protection des données

Mesures de conformité HIPAA:

Règlement	Exigence de conformité	Plage de pénalité
Règle de confidentialité HIPAA	Sécurité des informations sur la santé à 100% (PHI)	100 $ - 50 000 $ par violation
RGPD (protection des données de l'UE)	Compliance complète de l'accord de traitement des données	Jusqu'à 20 millions d'euros ou 4% du chiffre d'affaires annuel mondial
CCPA (Californie)	Protection de la confidentialité des données des consommateurs	100 $ - 750 $ par consommateur par incident

Protection de la propriété intellectuelle pour les technologies logicielles propriétaires

Portfolio de propriété intellectuelle de Veeva:

Catégorie IP	Nombre de brevets	Durée de protection des brevets
Technologies logicielles	37 brevets actifs	20 ans à compter de la date de dépôt
Algorithmes uniques	12 innovations enregistrées	Protection de 15 à 20 ans

Risques potentiels en matière de litige dans les implémentations de logiciels de technologie de santé

Analyse des risques de litige:

• Taux annuel des litiges de mise en œuvre du logiciel: 3,7%
• Coût moyen du litige: 425 000 $ par cas
• Temps de résolution typique: 18-24 mois

Paysage réglementaire complexe pour les logiciels médicaux et les solutions de gestion des données

Paysage de conformité réglementaire:

Corps réglementaire	Exigences de conformité	Fréquence de vérification
FDA	21 CFR Part 11 Records électroniques	Audit complet annuel
EMA (Agence européenne des médicaments)	Bonnes directives de pratique clinique	Certification biennale
Nist	Adhésion au cadre de cybersécurité	Surveillance continue

Veeva Systems Inc. (VEEV) - Analyse du pilon: facteurs environnementaux

Réduction de l'empreinte carbone via des solutions logicielles basées sur le cloud

La plate-forme basée sur le cloud de Veeva Systems démontre des avantages environnementaux importants grâce à une réduction des émissions de carbone. L'infrastructure cloud de l'entreprise permet:

Métrique de réduction du carbone	Impact quantitatif
Les émissions annuelles de CO2 évitées	3 742 tonnes métriques
Amélioration de l'efficacité énergétique du serveur	Réduction de 37% par rapport aux solutions sur site
Évaluation de durabilité des infrastructures cloud	ISO 14001: 2015 certifié

Efficacité énergétique dans les opérations du centre de données

Les opérations du centre de données de Veeva se concentrent sur la gestion durable de l'énergie:

Métrique de l'efficacité énergétique	Données de performance
Efficacité de l'utilisation du pouvoir (PUE)	1.2 (référence de l'industrie)
Utilisation des énergies renouvelables	68% de l'énergie totale du centre de données
Économies d'énergie annuelles	2,1 millions de kWh

Transformation numérique réduisant la documentation sur les soins de santé sur papier

Impact environnemental de la documentation numérique:

• Réduction du papier annuel estimé: 127 500 kg
• Traitement des documents numériques: 94% de la documentation totale
• Équivalent de préservation des arbres: 1 725 arbres par an

Initiatives de durabilité des entreprises dans l'infrastructure technologique

Initiative de durabilité	Métriques d'implémentation
Investissement informatique vert	3,6 millions de dollars en 2023
Programme de recyclage des déchets électroniques	92% des équipements électroniques recyclés
Année cible de neutralité en carbone	2030

Veeva Systems Inc. (VEEV) - PESTLE Analysis: Social factors

The social factors impacting Veeva Systems Inc. are deeply rooted in the global shift toward more efficient, patient-focused healthcare and the company's own Public Benefit Corporation (PBC) structure. This environment creates strong, long-term demand for digital solutions that accelerate drug development and improve patient experiences. Veeva is defintely well-positioned to capitalize on this societal need.

Core mission is to accelerate life-saving work, aligning with public demand for faster drug development.

Veeva's core business is inherently aligned with a powerful social imperative: advancing life-saving and life-improving work. As a Public Benefit Corporation (PBC), Veeva is legally committed to balancing the financial interests of shareholders with the pursuit of a public benefit purpose. This mission directly addresses the public's demand for faster, safer access to new medicines, a critical social need. The company's software helps streamline the complex processes within life sciences, from clinical trials to commercialization, which ultimately speeds up the time it takes to get treatments to patients.

This mission-driven focus is a significant social advantage, helping to attract and retain top talent who want to work for a company with a clear, positive societal impact.

Trend toward patient-centricity and personalized medicine drives demand for better data solutions.

The healthcare industry is rapidly moving away from a one-size-fits-all model to one centered on the patient experience and personalized medicine. This social trend is a massive tailwind for Veeva, as patient-centricity requires a sophisticated, connected data ecosystem that its products provide. For example, the use of Veeva ePRO (electronic Patient-Reported Outcomes) in clinical trials is growing rapidly because it makes the trial experience easier for patients via a simple mobile application.

The demand for better data solutions is evident in the adoption rates of patient-focused tools:

• Veeva ePRO Adoption: Serving more than 4 times the sites and patients in FY2025 compared to the prior year.
• Clinical Data Focus: The 2025 Clinical Data Trend Report emphasizes that patient optionality is now the real goal of decentralized clinical trials (DCT).

This shift to patient choice and diversity in trials is a social factor that necessitates the kind of platform-based approach Veeva offers to manage data seamlessly across all stakeholders, including patients and research sites.

Focus on high-quality employment, adding 119 employees in FY2025 without layoffs.

A key part of Veeva's PBC purpose is providing high-quality employment opportunities. The company maintains a strong focus on hiring and development, which contributes to its reputation and ability to attract talent in a competitive tech market. For the fiscal year ended January 31, 2025 (FY2025), the company's official filings show a clear commitment to growth without widespread workforce reductions.

Here's the quick math on their workforce growth:

Metric	Value (as of Jan 31, 2025)	Year-over-Year Change
Total Employees (FY2025)	7,291	+119 employees
Employee Growth Rate (FY2025)	1.66%	Down from 6.35% in FY2024

The net addition of 119 employees in FY2025 demonstrates a measured, strategic approach to hiring, even as the growth rate slowed compared to the prior year's 428 new hires. This stability is a significant social factor that enhances employee trust and corporate reputation.

Increased need for simplified, unified customer engagement models for Healthcare Professionals (HCPs).

The complexity of modern therapeutics and the sheer volume of data have created a social need for biopharma companies to simplify how they engage with Healthcare Professionals (HCPs). HCPs want fast, on-demand access to scientific information, pushing the industry toward a unified, customer-centric model. Veeva's commercial solutions, like Veeva CRM, directly address this by enabling a single view of the customer across commercial, medical, and marketing teams.

This unified approach is crucial because disconnected systems make it harder to deliver a cohesive experience. The company's own 2025 Pulse Field Trends Report highlights the opportunity here:

• Content Underuse: Field teams share materials in fewer than half of customer interactions.
• Impact of Relevance: Content-driven HCP engagement doubles treatment starts.

Biopharmas must simplify their processes to meet this social expectation, and Veeva's focus on connected systems and AI-powered insights is the clear action to take.

Veeva Systems Inc. (VEEV) - PESTLE Analysis: Technological factors

Major strategic shift to Veeva Vault CRM off the Salesforce platform is underway

The most significant technological pivot for Veeva Systems is the strategic move to transition its flagship Customer Relationship Management (CRM) product from the underlying Salesforce platform to its proprietary Veeva Vault CRM. This shift is driven by the goal of offering a unified, life sciences-specific platform, giving Veeva total control over its innovation roadmap and compliance framework. The non-renewal of the agreement with Salesforce officially concludes in September 2025, but the customer migration is already in full swing.

This is not a small lift; it's a massive, multi-year undertaking for the industry. While most migrations are slated for 2026 through 2029, the early adoption signals strong momentum. For example, GSK is a key early mover, with a plan to bring 19,000 users in 50 countries live on Vault CRM by late 2025. As of Q3 FY2026, Veeva Vault CRM has 115 customers live worldwide, including commitments from nine of the top 20 pharmaceutical companies. That's a strong endorsement. The table below shows the key drivers behind this monumental platform separation.

Strategic Driver	Technological Implication	FY2025/FY2026 Impact
Platform Independence	Faster, life sciences-specific feature releases	Innovation focus shifts entirely to Vault CRM.
Unified Ecosystem	Native integration of Commercial and R&D data	Vault CRM had 23 new customer additions in Q3 FY2026.
Compliance & Security	End-to-end data governance under one roof	Attracts major biopharmas like GSK, which is migrating 19,000 users by late 2025.

Heavy R&D investment of $693 million in FY2025 focuses on new product innovation

Veeva's commitment to technological leadership is clear in its financials. Research and Development (R&D) is consistently the company's largest expense category, and in fiscal year 2025 (FY2025), the company invested a substantial $693 million into R&D. This investment represented roughly 25% of total revenue for the year, a high reinvestment rate typical of a growth-focused software company.

The focus is on innovation across the entire product portfolio, especially in the Vault ecosystem. For the first nine months of the current fiscal year (ending October 31, 2025, or Q3 FY2026), R&D expenses totaled $568,593 thousand, reinforcing the accelerating pace of development. This money fuels the development of new modules, deeper AI integration, and the continued build-out of the Development Cloud, which is now the majority revenue segment. Honestly, this sustained R&D spend is the engine of their entire competitive moat.

Aggressive integration of AI (e.g., Vault CRM Bot, MLR Bot) to automate complex compliance workflows

Veeva is aggressively embedding Artificial Intelligence (AI) directly into its core applications to automate compliance-heavy and repetitive life sciences workflows. This isn't about general-purpose AI; it's deep, industry-specific application. Two key examples of this strategy are the Vault CRM Bot and the MLR Bot, both planned for availability in late 2025.

The Vault CRM Bot is a Generative AI (GenAI) assistant for the field sales force, embedding a Large Language Model (LLM) of the customer's choice right into the CRM. It helps reps with tasks like pre-call planning, suggesting next-best actions, and recommending compliant content. Plus, the new AI-powered Voice Control will enable hands-free operation.

The MLR Bot is a breakthrough application within Vault PromoMats, designed to streamline the Medical, Legal, and Regulatory (MLR) content review process. Available to early access customers as of the July 2025 release (25R2), it uses a Veeva-hosted LLM to perform automated quality checks before manual review, significantly reducing the back-and-forth and speeding up time-to-approval. Its checks cover things like:

• Editorial accuracy and brand guidelines.
• Regulatory compliance and risk flagging.
• Verification of required links and accessibility standards.

Development Cloud adoption is accelerating, unifying R&D processes for large biopharmas

The Development Cloud, which unifies processes across Clinical, Regulatory, Quality, and Safety functions, is now Veeva's largest growth opportunity and is seeing accelerating adoption, especially among the largest pharmaceutical companies. For the nine months ended October 31, 2025, the R&D Solutions segment accounted for 55% of total revenues, a clear indicator of this market shift. This segment's subscription revenue surged by 20.8% year-over-year in Q1 FY2026 alone, reaching $329 million.

The platform's strength lies in its ability to unify disparate R&D processes, replacing legacy systems with a single, compliant cloud environment. This is a huge win for efficiency. In the third quarter of fiscal year 2026, three top 20 biopharmas selected Development Cloud applications as their enterprise standard, with one selecting Veeva Study Startup, one for Veeva Study Training, and one for Veeva Safety. Notably, in the newer Veeva Safety area, the third top 20 biopharma went live in Q3 FY2026, signaling that the industry is modernizing pharmacovigilance and moving away from fragmented solutions. The Development Cloud is defintely where the future revenue is coming from.

Veeva Systems Inc. (VEEV) - PESTLE Analysis: Legal factors

The legal landscape for Veeva Systems Inc. is less about avoiding fines and more about being the central, trusted partner for one of the world's most heavily regulated industries. You can't operate in life sciences without absolute regulatory precision, so Veeva's legal risk is intrinsically tied to its product quality and compliance features.

This reality means legal and regulatory compliance is a core product feature, not a cost center, but still requires constant, high-stakes attention to global data laws and competitive moves.

Business is highly dependent on strict global regulatory compliance (FDA, EMA, GxP)

Veeva's entire business model hinges on its software meeting the stringent standards of global health authorities. This includes the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and various Good Practices (GxP) regulations covering manufacturing, clinical, and laboratory processes. If the Vault platform fails to maintain compliance, the entire life sciences value chain-from clinical trials to commercialization-is at risk.

For fiscal year 2025, the focus on compliance remains intense, especially in the clinical space. A 2025 Veeva MedTech Clinical Benchmark report showed that for medtech organizations, reliance on manual processes (32%) and complying with global trial regulation (18%) were cited as top hurdles in clinical affairs, which is exactly where Veeva's Vault Clinical Platform provides a solution. This is a perpetual, high-stakes legal requirement.

Data privacy regulations like GDPR and CCPA necessitate robust data handling and security features

Operating globally means Veeva must navigate a patchwork of complex data privacy laws, which carry massive financial and reputational penalties for non-compliance. The European Union's General Data Protection Regulation (GDPR) and the California Consumer Privacy Act (CCPA) are the most prominent examples, requiring deep-seated security and data handling features in every product.

For Veeva, the legal risk is tied to its role as a processor of sensitive health data (Protected Health Information, or PHI). The company's financial filings for the period ending October 31, 2025, consistently cite 'security, or privacy of our products' as a key risk factor. Honestly, this is a non-negotiable cost of doing business; you simply cannot serve global pharmaceutical companies without airtight data governance.

• Embed data audit trails for GxP-regulated content.
• Ensure data residency options to comply with local laws.
• Provide tools for customer data anonymization and consent management.

The legal framework of being a Public Benefit Corporation (PBC) requires annual public impact reporting

In February 2021, Veeva Systems became the first public company to convert to a Delaware Public Benefit Corporation (PBC). This is a legal commitment that goes beyond standard corporate social responsibility; it requires the Board of Directors to legally balance the financial interests of shareholders with the best interests of other stakeholders.

The PBC structure mandates an annual public impact report, which Veeva published for the 2025 fiscal year. The company's public benefit purpose is two-fold: to make the industries it serves more productive and to create high-quality employment opportunities. This legal structure ensures long-term strategic decisions are not solely driven by short-term shareholder returns. It's a defintely smart move for a long-term industry partner.

PBC Legal Requirement	Veeva's Fiscal Year 2025 Metric/Action
Legal Mandate to Balance Stakeholder Interests	Decision to not block integrations to third-party software, enabling them through open APIs.
Public Benefit Purpose: Create High-Quality Employment	Added 119 employees in fiscal 2025, ending the year with close to 7,300 employees globally.
Public Benefit Purpose: Advance Industry Productivity	Vault EDC used in more than 1,400 clinical trials globally, enabling faster study builds.

Potential legal/competitive scrutiny from the CRM migration, though support remains until 2030

Veeva is executing a massive, multi-year strategic move: migrating its legacy Veeva CRM (built on the Salesforce platform) to its proprietary Vault CRM. This transition, while strategic, creates a period of elevated legal and competitive risk. The migration of existing customers began in 2025, with the majority of migrations expected between 2026 and 2029.

The hard deadline is clear: support for the legacy Veeva CRM will cease in September 2030. This forced migration could open the door to competitive legal scrutiny, though Veeva is mitigating this by providing a long transition window. Plus, the company has been proactive in its own legal actions, taking legal action against IQVIA to stop what it believes are anti-competitive practices that harm the life sciences industry and violate antitrust laws.

Here's the quick math: customers have about five years from the start of the migration in 2025 to complete the switch before the 2030 support cutoff. That's a tight timeline for large, complex pharmaceutical companies.

Veeva Systems Inc. (VEEV) - PESTLE Analysis: Environmental factors

Committed to Science Based Targets initiative (SBTi) to reduce absolute Scope 1 and 2 GHG emissions by 58.8% by FY2035

You need to know where Veeva Systems Inc. stands on climate action, and the commitment is concrete: the company's targets are validated by the Science Based Targets initiative (SBTi), aligning its operations with the 1.5°C pathway. This is a crucial signal to investors and customers. Specifically, Veeva is committed to reducing absolute Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 58.8% by the end of Fiscal Year 2035 (FY2035), using FY2024 as the baseline.

Also, the company is tackling its most significant footprint area-the supply chain-with a parallel target. It aims to decrease Scope 3 emissions from purchased goods and services and capital goods by 63.8% per million USD gross profit added within the same FY2035 timeframe. This focus on Scope 3 is critical because it represents the vast majority of their total emissions, which is typical for a software company.

Fiscal Year 2025 total Greenhouse Gas (GHG) emissions were 55,006 metric tons $\text{CO}_2\text{e}$

For Fiscal Year 2025 (FY2025), which ended January 31, 2025, Veeva Systems Inc. reported total GHG emissions of 55,006 metric tons ($\text{MT}$) of $\text{CO}_2\text{e}$ (location-based). Here's the quick math: nearly all of this footprint is outside the company's direct control, which is the challenge of a cloud-based model. Scope 3 emissions alone accounted for 54,451 $\text{MT}$ $\text{CO}_2\text{e}$, or about 98.9% of the total.

The breakdown shows the relatively small direct operational footprint (Scope 1 and 2) compared to the upstream and downstream activities (Scope 3). The largest contributors in Scope 3 are Purchased Goods & Services, Business Travel, and Employee Commuting. This is why the Scope 3 reduction target is so important to their overall environmental strategy.

GHG Emission Scope	FY2025 Emissions ($\text{MT}$ $\text{CO}_2\text{e}$)	Percentage of Total (Location-Based)
Scope 1 (Direct Emissions)	253	0.46%
Scope 2 (Location-Based, Purchased Energy)	302	0.55%
Scope 3 (Value Chain Emissions)	54,451	98.99%
Total GHG Emissions (Location-Based)	55,006	100%

Cloud-based software inherently reduces clients' on-premise hardware and energy consumption

The core business model itself is an environmental advantage for your customers. By providing cloud-based systems like Veeva Vault and Veeva CRM, Veeva offers a significantly more energy-efficient option than the traditional on-site technology infrastructure used by life sciences companies. This shift helps clients lower their own environmental footprint by reducing the need for on-premise servers, cooling, and hardware maintenance. It's a win-win.

This inherent benefit is a major selling point in a market increasingly focused on Environmental, Social, and Governance (ESG) performance. Veeva's platform also enables customers to streamline processes and manage compliance in a paperless way, further reducing waste and resource consumption in clinical trials and regulatory filings.

• Eliminate paper-based processes in R&D and quality management.
• Reduce client energy use by replacing on-site servers with cloud infrastructure.
• Provide a paperless validation solution for system documentation.

Environmental Management System (EMS) aligns with ISO 14001 for continuous improvement

Veeva Systems Inc. maintains a formal Environmental Management System (EMS), which is a key component of its commitment as a Public Benefit Corporation (PBC). This EMS is aligned with the internationally recognized standard, ISO 14001:2015. This certification, which is valid through December 6, 2025, provides a structured framework for the company to manage its environmental impact and pursue continuous improvement.

The EMS covers a broad scope of activities, including professional services, product development, customer support, and commercial activities. This means the commitment to environmental responsibility is integrated across the entire business, not just in data centers. The formal system outlines their commitment to pollution and emissions reduction, energy and water efficiency, and waste reduction. It's a solid operational foundation for meeting those aggressive SBTi targets.